Development of Wheezing in Patients with Cough Variant Asthma During an Increase in Airway Responsiveness
Overview
Affiliations
Two theories explaining the mechanism for the manifestation of cough without wheeze in patients with cough variant asthma (CVA) are either a higher wheezing threshold or a milder degree of airway hyperresponsiveness. A significant proportion of patients diagnosed as having CVA eventually develop wheezing. The aim of this study was to investigate whether this change in the manifestation of asthma was associated with a decrease in wheezing threshold and/or an increase in airway hyperresponsiveness. Thirty-six children (7-15 yrs) with CVA were prospectively studied for 4 yrs. Bronchial provocation tests with methacholine using the stepwise increasing concentration technique were performed annually to measure the provocative cumulative dose producing a 20% fall in forced expiratory volume in one second (PD20). Wheezing thresholds were additionally determined at the initiation of and the end of the study (development of wheezing, or after 4 yrs). Sixteen (Group 1) of 29 patients available for the follow-up developed clinical wheezing during the period; 13 patients (Group 2) stayed as CVA or their cough resolved. There was no significant change in wheezing thresholds from the initiation to the end of the study (Group 1: 40.9+/-8.2% versus 40.2+/-8.3%; Group 2: 41.4+/-7.1% versus 40.1+/-7.3%). Methacholine PD20 (geometric mean, range of 1 SD), expressed as breath unit (BU), significantly decreased in Group 1 patients as they developed wheezing (initial versus wheezing year: 60.8 BU, 29.2-126.5 versus 32.8 BU, 11.5-93.3; p<0.01), whereas the value did not change in Group 2 patients (initial versus after 4 yrs: 85.3 BU, 45.2-161.1 versus 84.3 BU, 39.7-179.1; NS). The results suggest that an increase in airway hyperresponsiveness, but not a decrease in wheezing threshold, may have a pathogenetic role in the development of wheezing during the course of cough variant asthma in childhood.
Bibliometric Analysis of Cough Variant Asthma from 1993 to 2022.
Zhu Z, Wu J, Chen W, Luo F, Zhao X J Asthma Allergy. 2024; 17:517-537.
PMID: 38855058 PMC: 11162189. DOI: 10.2147/JAA.S452097.
Rouadi P, Idriss S, Bousquet J, Laidlaw T, Azar C, Al-Ahmad M World Allergy Organ J. 2021; 14(12):100618.
PMID: 34963794 PMC: 8666560. DOI: 10.1016/j.waojou.2021.100618.
Wang Y, Zhao L, Chen F, Guo Y, Ma H, Han B Can Respir J. 2021; 2021:9954411.
PMID: 34457097 PMC: 8397554. DOI: 10.1155/2021/9954411.
Xia Q, Liu M, Li H, Tian L, Qi J, Zhang Y Evid Based Complement Alternat Med. 2020; 2020:3829092.
PMID: 33178315 PMC: 7647767. DOI: 10.1155/2020/3829092.
Sugawara H, Saito A, Yokoyama S, Tsunematsu K, Takahashi H Respir Res. 2019; 20(1):41.
PMID: 30808365 PMC: 6390374. DOI: 10.1186/s12931-019-1005-2.